Decode - 500 Beiträge pro Seite

[islandia]

Hi, diese Aktie wurde seit langem nicht mehr diskutiert. Ich habe neulich bei €4,40 richtig aufgestockt. Bei $10 könnte es richtig interessant werden, frei bis $30? Vor dem Börsenlisting wurden Graumarktkurse bis $60 bezahlt. Angeblich viele Neuigkeiten in nächster Zeit. Anfang 2004 soll das erste Produkt auf den Markt kommen, siehe auch unten. Hoffe auf einige Antworten.



LONDON, Oct 17 (Reuters) - Iceland`s deCODE genetics Inc. (NasdaqNMCGN - News) and Swiss group Roche Holding AG (ROCZg.VX) on Friday said they plan to develop a DNA-based test to identify heart attack sufferers, pushing deCODE`s stock up nearly 34 percent.

ADVERTISEMENT


The move follows the discovery by their scientists of forms of a gene that confer twice the average risk of myocardial infarction, or heart attack.

Reykjavik-based deCODE, which uses the small, isolated population of Iceland to examine the genetic basis of common diseases, will receive an unspecified milestone payment from Roche following the discovery.

Shares of deCODE rose $1.72, or 33.9 percent, close at $6.79 on the Nasdaq on Friday.

The two firms are working on a range of diagnostic tests that could be worth up to $300 million in funding, milestone payments and royalties to the Icelandic biotechnology company.

Diagnostic tests typically take two or three years to develop, significantly faster than the time taken to produce new drugs.

Kari Stefansson, deCODE`s chief executive, said a test for heart attack risk would allow patients and their doctors to take preventive steps to minimize the danger. This might include taking drugs, as well as changing diet and lifestyle.

DeCODE mapped the gene link after studying DNA from 2,000 patients and unaffected relatives from families across Iceland. They found two common forms of a single gene that conferred risks equal to or greater than other well-known risk factors, such as smoking, high blood pressure, high cholesterol or diabetes.

[proFEiT]

in meinem Chartanalysedepot ist Decode mit 93% im Plus , leider ist dieses nur virtuell.
Aber ich bin kein Chartexperte. In dieser Formation vor einiger Zeit sah ich -als Chartlaie wohlgemerkt- eine Bärenfalle, die sich ja bewahrheitete. Wenn ich nicht woanders investiert wäre, hätte ich sicherlich einen Batzen gekauft
Um dieses Papier nicht zu vergessen, nahm ich sie also u.a. neben Getty Images(+20%) und Viisage Tech. in mein "virt. Chartdepot" auf:


Depot Chartanal.[5000:1000=5]


Name / Stück / Kurs / Einst. / Kauf / Gewinn in %

Decode Genetics 210 8,96 $ 4,75 $ 23.09.03 884,10 $
88,63 %
Getty Images 20 42,61 $ 35,33 $ 23.09.03 145,60 $
20,61 %
Viisage Technology Inc 200 3,86 $ 4,12 $ 23.09.03 -52,00 $
-6,31 %


Depotwert 977,70 € 38,67 % 3.505,80 €
Kontostand 2.471,90 €
Summe 5.977,70 €


Fazit: als ChartLaie halte ich mich doch nicht schlecht

[islandia]

Und wo liegt dein virtuelles Preisziel?

[Erbse1]

Heute im E-mail Verteiler
FOR IMMEDIATE RELEASE


Contacts:
deCODE genetics Euro RSCG Life NRP
Edward Farmer Joy Bessenger Ernie Knewitz
[phone] [phone] [phone]
[e-mail] [phone] [e-mail]
[e-mail]



deCODE Licenses Developmental Compound, Expects to Start Enrollment for Phase II Clinical Trial in Myocardial Infarction at the Beginning of Next Year


Reykjavik, ICELAND, November 17, 2003 — deCODE genetics (NasdaqCGN) today announced that it has acquired an exclusive worldwide license from Bayer AG to develop and commercialize a small molecule compound. The compound is active against a key target, located within an inflammatory pathway, made by a gene isolated at deCODE that predisposes to myocardial infarction, or heart attack. The compound, DG031, has been shown in previous clinical work in a different indication to be well-tolerated and with no major safety issues. deCODE plans to test it for efficacy in preventing heart attack in an information-rich Phase II clinical trial, enrollment for which is expected to start at the beginning of next year. deCODE plans to provide additional detail on the target and the compound in a scientific article to be submitted at the beginning of the clinical trial. Bayer will receive milestones as the compound advances towards market approval, as well as royalties on sales of the compound as a marketed drug.

“This is a transforming event for deCODE. By licensing an existing compound already found to be well-tolerated, designed against one of our key targets in myocardial infarction, we will be able to leapfrog several stages in the drug development process. We are now in a position to advance by a matter of years the expected timeframe for turning our breakthrough discoveries in the genetics of heart attack into new drugs to combat the biggest killer in the industrialized world,” said Kari Stefansson, CEO of deCODE. “Our discovery of genes that confer risk for heart attack gives us a strong advantage when it comes to conducting an efficient and cost-effective clinical trial that can gauge the compound’s effectiveness in preventing heart attack in a large and well-defined cohort. The licensing of this compound complements our solid intellectual property portfolio in this area, and we believe represents a major opportunity to capture the value from our research into the genetics of heart attack.”

By applying its discovery of genetic risk factors for heart attack, as well as extensive clinical and geneaological data, deCODE has designed a large Phase II clinical trial that provides a significant expected baseline number of cardiovascular events per year. Because the cohort is well characterized both clinically and genetically, the company believes that it can conduct a trial gauging the efficacy of this compound in reducing the number of events in two years. This trial will also enable an analysis of the results in relation to a variety of known risk factors — such as diabetes, obesity, cholesterol levels, high blood pressure, c-reactive protein and myeloperoxidase — in addition to the generation of pharmacogenomic data on the impact of genetic and clinical factors on drug response. Dr. Eric Topol, chairman of the department of cardiovascular medicine at the Cleveland Clinic, will participate as a principal advisor in the design and conduct of the planned clinical trial.

[islandia]

UPDATE - DeCODE accelerates drug programme with Bayer deal
Monday November 17, 9:54 am ET
By Ben Hirschler, European Pharmaceuticals Correspondent


(Adds deCODE share rise, paragraph 6)
LONDON, Nov 17 (Reuters) - Iceland`s deCODE genetics Inc (NasdaqNMCGN - News) pushed the fast-forward button on its drug programme on Monday by acquiring worldwide rights to a drug from Bayer AG (XETRA:BAYG.DE - News) that may prevent heart attacks in some patients.

ADVERTISEMENT


The product will go straight into Phase II clinical trials, saving the Reykjavik-based biotechnology company several years in drug development.

DeCODE, which uses the small, isolated population of Iceland to examine the genetic basis of common diseases, will test the oral medicine for preventing heart attacks in a large two-year study starting early in 2004.

Drug firms normally have to spend several years on pre-clinical and Phase I trials before reaching this stage.

"By licensing an existing compound already found to be well tolerated, designed against one of our key targets in myocardial infarction (heart attack), we will be able to leapfrog several stages in the drug development process," said Kari Stefansson, deCODE`s chief executive.

DeCODE`s stock, which has rallied strongly in recent weeks on growing hopes for its product pipeline, gained more than six percent to hit a 22-month high of $9.55 in early Nasdaq trade.

Financial terms of the worldwide exclusive licence deal were not disclosed, and deCODE declined to say what disease the drug had originally been developed for.

Stefansson said the deal was a milestone for the Icelandic biotech company, which up to now has been focused on early stage genetics.

"This is a very important development for us in terms of bringing products to the market," he said.

Industry analysts believe deCODE could strike another drug deal in 2004 as well as continuing work on in-house discovery programmes and diagnostic tests.

GENE DISCOVERY

The Icelandic firm spotted the potential for Bayer`s compound after discovering a gene that, in different forms, can double the risk of heart attack.

With that knowledge, the company`s scientists were able to zero in on the drug as being active against a key target within an inflammatory pathway made by the gene.

Clinical trials of the drug, which will be conducted in Iceland, will segment patients according to their DNA profiles to see whether the drug works better for those with a genetic predisposition to heart attacks.

Stefansson declined to give the cost of the two-year testing programme but said the company had accounted for the investment in its financial projections for 2004.

[tui66]

diese Aktie verdient mehr Aufmerkasmkeit.
Chart wie mit demLineal gezogen.
Sehr interresanter Artikel im Aktionär Nr48.
Habe mir heute und gestern welche ins Depot gelegt.

tui66

[islandia]

Was stand im Aktionär?

[blaueberge]

hallo,

ich hab auch ein paar decodes hier rumliegen.
die hatte ich kurz nach dem börsengang erworben, für rund 23 Euro.

ich wohne auch nur ca. 2 km luftlinie von der firma entfernt und den guten kari stefansson kennt hier fast jeder. schliesslich ist er ständig in den medien oder man trifft ihn beim einkaufen.

ein paar bekannte arbeiten bei decode und die meisten von denen und auch einige andere bekannte, die nicht dort arbeiten haben aktien aus der anfangszeit.
die leute hier glauben an die firma und haben niemals dran gedacht, ihre stücke zu verkaufen.

ärgerlich, dass ich nicht eher flüssig war, aber jetzt denke ich wieder dran mir noch paar stücke ins depot zu legen.

leider bekomme ich hier nicht den aktionär, es würde mich sehr interessieren, was drin stand.

gruss aus reykjavik,
blaueberge

[tui66]

@blaueberge

war im Aktionär "Die letzte Seite" - leider habe ich z.Zt. keinen Scanner, ist zum Abschreiben zu lang.
Überschrift ist "Ein Labor namens Island". Es wird auf die Einzigartigkeit des Deals mit der isländischen Regierung hingewiesen, die Infos über Erbgut, Ahnentafeln und Patientendaten exclusiv für Forschungszwecke nutzen zu können. ...Preis dafür von 710.000 Dollar p.a. eigentlich bescheiden... bei den Chancen die sich ergeben...erste Früchte: Gene für Fettleibigkeit, Schlaganfall und Osteoporose erkannt.... Gentests geplant...1. mit Roche zum Thema Herzinfarkt....trotz 300% in diesem Jahr ist ein Ende der Erfolgsstory nocht nicht in Sicht.

akt. Kampf um 9$, war schon mehrfach drüber

Was gibt es bei Euch zu hören und zu lesen?
Für mich ist die Geschichte immer faszinierender je mehr ich darübernachdenke... Es ist wirklich ein reales Labor mitten im Leben. Weißt Du wie lange der Vertrag gilt?
gruss
tui66

[tui66]

Full Description

deCODE genetics, Inc., incorporated in 1996, is a population genetics company developing drugs and DNA-based diagnostics based upon its discoveries in the inherited causes of common diseases. The population approach and resources have enabled the Company to isolate genes and targets directly involved in the development of many of the biggest challenges to public health. The Company`s business is divided into two components, products and services. Its primary product focus is on the discovery and commercialization of novel therapeutics designed against targets identified in its population-based gene discovery work.

Through the 2002 acquisition of MediChem Life Sciences and its subsidiary, Emerald BioStructures, deCODE has integrated capabilities for applying genetics findings to the development of drugs, both through its own programs and in alliance with corporate partners. The Company is applying the links it has identified between genetic factors and disease to create DNA-based diagnostic and pharmacogenomic tests. It is also marketing software systems it has developed for making correlations between genetic variation and disease and drug response. The Company`s service offerings include contract service businesses in drug discovery and medicinal chemistry, through its Chicago-based pharmaceuticals group; three-dimensional protein crystallography products and contract services, through a Seattle-based biostructures group; pharmacogenomics and clinical trials services, through a wholly owned subsidiary, Encode; database services, through subscriptions to the Clinical Genome Miner system integrating anonymized population data on disease, genotypes and genealogy, and genotyping services through the genotyping laboratory in Reykjavik, Iceland.

Products

The products deCODE is developing include drugs, DNA-based diagnostic tests, pharmacogenomic tests and bioinformatics systems. Its drug and diagnostic development programs are based on genes and related targets it has identified through its population genetics research in approximately 50 common diseases.

The Company is pursuing the commercial development of its gene- and drug-target discovery programs through the development and marketing of drugs, DNA-based diagnostics, pharmacogenomic tests and bioinformatics systems it has developed for making correlations between genetic variation and disease. It is pursuing this strategy through the application of its own resources to turn discoveries from its internal projects into therapeutic or diagnostic products and developing its own marketing capabilities; by licensing its discoveries to others who will be required to pay it royalties on sales of any products developed using the results of its gene discovery programs, and by entering into collaborative arrangements for the development and marketing of products from these programs. Its most advanced drug discovery programs are in schizophrenia, stroke and peripheral arterial occlusive disease (PAOD). The Company is developing and plan to market pharmacogenomic tests that can, by analyzing genetic markers, identify individuals who are likely to respond well to specific drugs.

Services

The acquisition of MediChem provided the Company with its contract service business. MediChem, which has become the Company`s pharmaceuticals group, is a drug discovery technology and services company focused on using its high-throughput integrated chemistry platform to streamline genomics-based drug discovery and development. The group is focused on chemistry-based drug discovery and development ranging from early-stage lead discovery and optimization to the identification of viable synthetic routes required to manufacture materials in quantities for pre-clinical and clinical studies. It provides the Company, its partners and its contract customers with substantial expertise in structural proteomics; lead discovery and optimization; combinatorial, computational and medicinal chemistry; biocatalysis; analytical and separations chemistry; chemical synthesis and scale-up, and clinical trials management and regulatory approvals. The customer base of its pharmaceuticals group includes large pharmaceutical companies, biotechnology firms and patient organizations pursuing drug discovery for particular diseases.

In November 2000, deCODE launched Encode as a wholly owned subsidiary for pharmacogenomics and clinical trials. In addition to conducting pharmacogenomics work for its proprietary programs, Encode conducts pharmacogenomic studies for contract customers, as well as clinical trials on new and existing therapeutics for pharmaceutical companies.

Another of the Company`s service offerings is subscription to the Clinical Genome Miner (CGM), a computer-based discovery system that allows users to perform real-time analyses to study the association between variation in human genes and human disease. The CGM combines the statistical and datamining tools of the CGM Discovery system with the ability to conduct statistical queries of deCODE`s population data on genotypes, genealogy and disease.



als kleinen Überblick

[blaueberge]

Hi, das kam heute im email newsletter...


deCODE Isolates Two Major New Obesity Genes under Alliance with Merck

Common forms of these genes confer significant predisposition to obesity

Reykjavik, ICELAND, December 11, 2003 — deCODE genetics (NasdaqCGN) today announced that it has isolated two new genes as part of its alliance with Merck & Co, Inc. to develop drugs for the treatment of obesity. Following the gene discovery announced in September, deCODE scientists have discovered common versions of two additional genes that significantly predispose individuals to obesity. The companies are now analyzing the genes and the biological pathways they delineate to select optimal targets for the development of new drugs.

The genes were identified through population- and genome-wide linkage scans and association analyses of at-risk haplotypes utilizing genetic and clinical data from the 17,000 participants in deCODE’s obesity program in Iceland. The discovery of one of the genes resulted from the analysis of high-density SNP and microsatellite genotyping of more than 900 men with high body-mass index (BMI) and several hundred non-obese relatives and random controls. The at-risk haplotypes, or versions of the gene linked to obesity, were found in more than one in four individuals with high BMI, and were three times more common in these individuals than in controls. This gene, which the companies believe is involved in regulating how the body stores and uses energy, implicates a novel pathway in human obesity.

The at-risk versions of the second gene, which was identified through analysis of 125 families that include multiple women with a high percentage of body fat (PBF), were carried by 22% of those with high PBF. These haplotypes increase the risk of obesity by a factor of five. This gene appears to contribute to obesity through the regulation of appetite.

“These findings demonstrate yet again the power of our capabilities in human genetics for discovering major new targets and pathways involved in the most complex medical conditions. We have identified common alleles of genes that contribute significantly to both of the principal processes involved in obesity – basic energy metabolism on the one hand and the regulation of appetite on the other,” said Kari Stefansson, CEO of deCODE. “With our partners at Merck we are bringing together these findings with extensive work in mouse genetics and biology, giving us a strong starting point for beginning the development of novel drugs for the treatment of obesity.”

The prevalence of obesity continues to increase throughout the developed and developing world. Obesity, through its co-morbidities such as diabetes, lipid disorders, and hypertension, contributes greatly to human disease. Together, deCODE and Merck are working to identify novel mechanisms to be targeted by drugs for the treatment of obesity.


About deCODE
deCODE is using population genetics to create a new paradigm for healthcare. With its uniquely comprehensive population data, deCODE is turning research on the genetic causes of common diseases into a growing pipeline of products and services — in pharmaceuticals, gene and drug discovery, DNA-based diagnostics, pharmacogenomics, bioinformatics, and clinical trials. deCODE’s pharmaceuticals group, based in Chicago, and deCODE’s biostructures group, based in Seattle, conduct downstream development work on targets derived from deCODE’s proprietary research in human genetics as well as contract service work for pharmaceutical and biotechnology companies. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at www.decode.com.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE’s filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

[pegau]

Wer kauft denn heute zu diesen Kursen? 2300 Stk zu €7,0 bzw €7,05. Es entspricht über $8,8 wobei der Kurs der Aktie in den USA $8,28 am Freitag war. Es ist ca 7% Aufschlag. Weiss jemand was neues?

[pegau]

Nun wurden bis €7,25 (Xetra) bezahlt. Habe ich etwas verpasst?

[pegau]

Das neueste von Decode. Es wird doch immer interessanter zu sehen in wie viele Richtungen diese Firma sich entwickelt.

deCODE and The Simons Foundation Launch Major Population-based Study of the Genetics of Autism
Wednesday January 7, 5:00 am ET


REYKJAVIK, Iceland, Jan. 7 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN - News) and The Simons Foundation, a New York-based organization supporting advanced research in the basic sciences, today announced the launch of the first ever population-based study of the genetics of autism and autism spectrum disorders (ASDs). Funded by a two-year, $2.8 million grant from The Simons Foundation, deCODE has begun a population- and genome-wide gene discovery effort aimed at identifying the key genetic components of these disorders. It is well established that these conditions run in families, but the identification of the specific inherited causes may provide valuable insight into the neurological dysfunctions they evoke. Knowledge of the biology of these disorders may in turn clarify the role of environmental factors and contribute to the development of new methods of diagnosis and treatment.
ADVERTISEMENT


The deCODE study will bring together detailed genotypic and clinical data on individuals diagnosed with autism and ASDs, as well as genotypic data and information from detailed questionnaires on aspects of social communication and other behavioral characteristics from first and second degree relatives. In total, the study aims to include several hundred individuals with autism and ASDs, and several thousand of their relatives. The ability to assemble such comprehensive clinical and behavioral data for population-wide linkage analysis offers an unprecedented opportunity not only for identifying key genes linked to these disorders but also for pinpointing which elements of these complex phenotypes are inherited.

In this program the deCODE team is working with the National Diagnostic and Counseling Center, which carries out diagnostic evaluations and oversees therapy for children and adolescents with autism and related spectrum disorders throughout Iceland, as well as the Icelandic Autism Support Network, an organization of families and caregivers, and physicians and psychologists at the Department of Child and Adolescent Psychiatry at the National University Hospital. Dr. Catherine Lord of the University of Michigan, a renowned expert in this field, is serving as a clinical advisor, assisting the deCODE team in the development and analysis of the questionnaires that will be given to family members. The questionnaires are designed to capture often subtle behavioral and personality traits which, although not clinically relevant on their own, may in certain combinations or in extreme forms constitute important components of these disorders.

"We are very excited to begin tackling the genetics of autism and autistic spectrum disorders. Our discoveries in other neurological and behavioral disorders like schizophrenia, anxiety and depression demonstrate that our population approach has the power to pull out major genes even in the most complex disorders the basic biology of which is little understood. I am confident that we will succeed in autism as well, and we and our collaborators are very grateful to the Simons Foundation for their support for this project," said Kari Stefansson, CEO of deCODE.

"We are very pleased to be working with deCODE on this project. It represents a crucial component in our foundation`s new program to search out the root causes of autism, a condition which affects very many people around the world. We believe that deCODE`s proven expertise has a great chance to prove highly successful and we are delighted to be associated with so fine an organization," said Jim Simons, founder of the Simons Foundation.

About autism

Autism and autism spectrum disorders are a group of complex neurodevelopmental disorders involving a range of delays and difficulties in social interaction and communication skills. Individuals with autism spectrum disorders, such as Asperger`s Syndrome and certain Pervasive Developmental Disorders, exhibit developmental problems in some but not all of the areas as do those with autism. The number of people diagnosed with autism and ASDs has risen rapidly in recent years, although because so little is known about the neurological and environmental causes of these disorders it is unclear whether this increase is due to better diagnosis or to an actual increase in the prevalence of the phenotype. According to the Centers for Disease Control, these disorders may affect as many as 1 in every 250 people in the U.S.

About deCODE

deCODE is using population genetics to create a new paradigm for healthcare. With its uniquely comprehensive population data, deCODE is turning research on the genetic causes of common diseases into a growing pipeline of products and services -- in pharmaceuticals, gene and drug discovery, DNA- based diagnostics, pharmacogenomics, bioinformatics, and clinical trials. deCODE`s pharmaceuticals group, based in Chicago, and deCODE`s biostructures group, based in Seattle, conduct downstream development work on targets derived from deCODE`s proprietary research in human genetics as well as contract service work for pharmaceutical and biotechnology companies. deCODE is delivering on the promise of the new genetics(SM). Visit us on the web at www.decode.com .

About The Simons Foundation

The Simons Foundation is a private family foundation based in New York City, whose primary mission is to fund advanced research in science and mathematics. A secondary mission of the foundation is to help children with learning differences. Bridging these two areas, the Simons Foundation has recently undertaken a major initiative supporting research into autism and its treatment.

Any statements contained in this presentation that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE`s filings with the Securities and Exchange Commission. deCODE undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

[pegau]

Und noch eine PR.

Families of Spinal Muscular Atrophy and deCODE Open Screening Capabilities To Third-party Compounds
Wednesday January 7, 11:44 am ET
Latest Stage in Aggressive Drug Development Drive for Spinal Muscular Atrophy


LIBERTYVILLE, Ill., Jan. 7 /PRNewswire/ -- Families of Spinal Muscular Atrophy (FSMA), an organization founded to promote research leading to effective treatment of Spinal Muscular Atrophy (SMA), a debilitating and often fatal disease, today announced the next step in its partnership with deCODE genetics (Nasdaq: DCGN - News). FSMA and deCODE are making available deCODE`s high- throughput screening capabilities to test promising compounds that may increase SMN levels or supplement SMN function.
ADVERTISEMENT


Using compounds identified through previous FSMA-funded research, deCODE`s Chicago-based pharmaceuticals group has completed initial screening and is now working to optimize hits to obtain the best activity and drug like properties. FSMA and deCODE are now hoping to collaborate with other parties in order to make available the necessary chemistry resources to progress other potentially effective compounds through the evaluation process. These services will be made available under the current collaboration that is being funded by FSMA.

SMA is a genetic disorder involving the deletion or mutation of one or both copies of the Survival Motor Neuron (SMN1) gene on chromosome 5. This causes a chronic deficiency in the production of the SMN protein, essential to the proper functioning of the motor neurons in the spinal cord and to the control of muscles in the limbs, neck and chest. The initial hits developed by FSMA and deCODE increase expression of the SMN2 gene, raising the level of SMN protein.

"Families of SMA is committed to finding a cure for SMA," said Audrey Lewis, executive director of FSMA. "With deCODE we have made significant strides in identifying promising new compounds, and we want to extend this effort to identify any and all compounds that may lead to an effective treatment or cure for SMA."

FSMA-sponsored research has contributed not only to the identification of both the SMN1 and SMN2 genes. Previous FSMA-sponsored drug discovery work has identified a series of compounds that may increase the expression of the SMN2 gene and thus the amount of fully functional protein produced. If a compound can be found that can do this safely and effectively, it may be possible to restore the proper amount of SMN protein in the body and slow or reverse the disease process. deCODE`s current work for FSMA focuses on identifying and developing such a compound.

"We are pleased to be bringing to our collaboration with FSMA the full capabilities of an experienced drug discovery partner," said Kari Stefansson, CEO of deCODE. "We are committed to helping FSMA develop new experimental drugs for therapy of SMA as quickly and effectively as possible."

In the U.S. alone there are more than 7 million carriers of the genetic risk factors for SMA, and the disease affects approximately one in every 6000 live births. SMA is usually diagnosed when babies are less than 18 months old, although certain types of the disorder can appear in later life.

About FSMA

Families of SMA is a volunteer-driven nonprofit organization based in Libertyville, IL. It was founded in 1984 by parents of children suffering from SMA. FSMA is the largest international organization dedicated solely to eradicating SMA by promoting and supporting research, helping families cope through informational programs and support, and educating the public and the medical community about SMA. The organization has more than 24 chapters worldwide and more than 5,000 member families and is a founding member of the International Alliance for Spinal Muscular Atrophy. FSMA has funded $16 million towards SMA research, and has already committed an additional $12 million over the next three years. In addition, FSMA has provided more than three million dollars in patient services, which includes an equipment pool, conferences, family newsletter and phone support. For more information visit the website www.curesma.com or call 1-800-886-1762.

About deCODE

deCODE is using population genetics to create a new paradigm for healthcare. With its uniquely comprehensive population data, deCODE is turning research on the genetic causes of common diseases into a growing range of products and services -- in pharmaceuticals, gene and drug discovery, DNA- based diagnostics, pharmacogenomics, bioinformatics, and clinical trials. deCODE`s pharmaceuticals group, based in Chicago, and deCODE`s biostructures group, based in Seattle, conduct downstream development work on targets derived from deCODE`s proprietary research in human genetics as well as contract service work for pharmaceutical and biotechnology companies. deCODE is delivering on the promise of the new genetics.(SM) Visit us on the web at www.decode.com .

[pegau]

Endlich bewegt sich Decode wieder, nach einigen doch recht positiven news. Heute um 10% im plus...

[tui66]

9,89 $
ist der Ausbruch geglückt?
Umsatz nicht schlecht!!

[pegau]

Nun sollte eine PR folgen. Hat jemand die Presentation gehört?

[tui66]

Ausbruch über 10$ geglückt!!
Vom Chart jetzt erstmal viel Luft nach oben ,
jetzt müssen nur noch die Instis kräftig einkaufen.

Aber da interessiert hier wohl niemand!!

[pegau]

Ja der Chart wird interessant. Ich verstehe auch nicht das Desinteresse hier für diesen Wert. Ist doch hochinteressant, mit vielen positiven Meldungen, viel Phantasie und grossen Partnern. Morgen ist ja auch ein wichtiger Tag für die Firma. Hier nur ein kleines Sortiment aus alten headlines, für alle diejenigen die doch ein kleines Interesse haben...

Reykjavik, Iceland and Woodridge, Illinois, January 8, 2002
deCODE genetics to Acquire MediChem Life Sciences
Acquisition of integrated chemistry capabilities to accelerate deCODE`s growth into a fully-integrated biopharmaceutical company

Reykjavik, Iceland, January 15, 2002
deCODE and Pharmacia Form Pharmacogenomics Alliance

Reykjavik, Iceland and Basil, Switzerland, January 29, 2002
deCODE and Roche Unveil New Alliance in Drug Discovery and Development
Alliance will leverage deCODE`s expanded drug development capabilities to turn gene discoveries under existing collaboration into new drugs for common diseases

Reykjavik, Iceland, June 9, 2002
deCODE Publishes High-resolution Genetic Map of the Human Genome

Reykjavik, Iceland and San Diego, CA, July 1, 2002
deCODE and Elitra advance alliance to discover novel antibiotics to fight drug-resistant bacteria

Reykjavik, Iceland, September 27, 2002
deCODE and Merck Form Landmark Alliance in Obesity
Alliance brings together world-leading capabilities in genetics and drug development to speed the discovery of new treatments

Reykjavik, Iceland, November 20, 2002
deCODE and Wyeth in Pharmacogenomics Collaboration
deCODE will apply its expertise in in vitro pharmacogenomics to provide gene expression data in relation to a Wyeth candidate treatment for respiratory disease

Reykjavik, Iceland, and Basel, Switzerland, January 9, 2003
deCODE and Roche Diagnostics Announce Identification of Significant Genetic Risk Factors for Osteoporosis
The companies will apply these discoveries to create a DNA-based diagnostic test to aid effective prevention of the disease

Reykjavik, Iceland, and Armonk, N.Y., January 23, 2003
deCODE and IBM Form Strategic Alliance to Deliver Technology Solution for Applying Genetics to Drug Discovery
Initiative to link knowledge about the human genome and disease also aims to improve diagnostic and treatment decisions

Reykjavik, Iceland, and Cambridge, Massachusetts, January 31, 2003
deCODE and Vertex Pharmaceuticals Sign Broad Agreement for Pharmacogenomics Built into Clinical Trials
Vertex will leverage deCODE`s ability to conduct pharmacogenomic analysis in parallel with clinical trials

Reykjavik, Iceland, and Libertyville, Illinois, February 12, 2003
deCODE and Families of Spinal Muscular Atrophy Launch Landmark Effort to Develop Effective Treatment for SMA
deCODE enlisted to carry out the latest stage in one of the most aggressive drug development drives ever undertaken by a family-based patients` organization

Reykjavik, Iceland, April 8, 2003
deCODE`s RoboHTC (TM) System to Support AstraZeneca`s Structure-based Drug Design Capabilities
RoboHTC is an integrated hardware and informatics solution for designing, generating, imaging, storing and annotating protein crystallization experiments

Reykjavik, Iceland, September 30, 2003
deCODE Announces Milestone in its Obesity Alliance with Merck
deCODE has discovered a gene with certain variations that predispose to obesity and others that predispose to thinness

Reykjavik, Iceland, and Basel, Switzerland, October 17, 2003
deCODE and Roche Diagnostics Announce Discovery of Significant Genetic Risk Factors for Heart Attack
DNA-based diagnostics applying these findings may enable more targeted, individualized prevention strategies

Reykjavik, Iceland, November 17, 2003
deCODE Licenses Developmental Compound, Expects to Start Enrollment for Phase II Clinical Trial in Myocardial Infarction at the Beginning of Next Year

Reykjavik, Iceland, December 11, 2003
deCODE Isolates Two Major New Obesity Genes under Alliance with Merck
Common forms of these genes confer significant predisposition to obesity

Reykjavik, Iceland, December 17, 2003
deCODE and Roche Announce Milestones in the Pharmacogenomics of Asthma and Hypertension
Simple gene expression assays used in clinical trials predicted response to common asthma and hypertension drugs with an average accuracy of 85%

[pegau]

Decode bricht schon wieder aus, aber hier will es so wie so keiner wissen. Schon wieder ohne neue News.

[blaueberge]

naja, es gibt schon ne news...
war gerade im newsletter:

FOR IMMEDIATE RELEASE

Contact:
deCODE genetics
Kristin Asgeirsdottir
[phone]
[e-mail]
deCODE genetics to Webcast Presentation at the 16th Annual Piper Jaffray Healthcare Conference


Reykjavik, ICELAND, January 23, 2004 ¯ deCODE genetics (NasdaqCGN) today announced that its presentation at the 16th Annual Piper Jaffray Healthcare Conference will be webcast live via streaming audio. deCODE management will provide an overview of deCODE’s business and a discussion of recent developments.

The company’s presentation will be delivered at 9amEST/2pmGMT on Thursday, January 29, 2004, at the Pierre Hotel in New York City. The webcast can be accessed through the Investors page on deCODE’s website, www.decode.com, or via the conference website at http://www.pjc.com/hccwebcast. Those interested in listening to the presentation should log on a few minutes in advance, in order to download any software or complete any sign-in that may be required.

About deCODE genetics
deCODE is using population genetics to create a new paradigm for healthcare. With its uniquely comprehensive population data, deCODE is turning research on the genetic causes of common diseases into a growing range of products and services — in pharmaceuticals, gene and drug discovery, DNA-based diagnostics, pharmacogenomics, bioinformatics, and clinical trials. deCODE’s pharmaceuticals group, based in Chicago, and deCODE’s biostructures group, based in Seattle, conduct downstream development work on targets derived from deCODE’s proprietary research in human genetics as well as contract service work for pharmaceutical and biotechnology companies. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at www.decode.com.

[blaueberge]

@pegau

will es denn woanders einer wissen?

[pegau]

Leider nicht vom mir zusammengeschrieben, vom RB board kopiert - aber dennoch gute Infos:

Most exciting news:

Summary from conference last week.
1) elaboration of MI Phase II trial starting in Feb with 900 high risk subjects projected to last 18 mos. HOWEVER, 300 of those subjects will have select biomarkers tracked and if data provide strong support for efficacy of drug, by late fall 04 deCode will go to FDA to ask for leap frog into Phase III trials.

2)While hypertension and asthma programs appear to be less advanced, both actually show the same profile as MI--in other words, deCode is investigating existing drugs developed by big pharma which target the genes identified by deCode as implicated in hypertension and asthma--SO, it is possible that deCode could move directly into phase II trials in one or both disease program.

3)reiterated PAOD phase I trial/IND filing by the end of 04 with rapid movement through phase I and II trials.

4)Phase I clinical trials for Stroke to start end of 04 or early 05.

5)reiterated pending announcement of significant new partnership with a big pharma to conduct information rich clinical trials

6)reiterated 04 launch of osteoporosis diagnostics with Roche and indicated progress in cardiovascular diagnostics. Explained that all diagnostic products will be partnered. Did not mention cancer diagnostics, but Kari said at JP Morgan that "formidable progress in cancer diagnostics" would be announced very soon. We should know more about this by Feb. 17th earnings report if not sooner.

7)Explained business model of using services such as pharmacogenomics to fund drug and diagnostic development and reiterated achieving break even cash flow.
8)reiterated that the number of druggable targets (now at 15) will double in 04 and several new drugs may be developed.
Hold on to your hats and your stock, folks. 2004 is going to be a great year for deCode.

[MONSIEURCB]

Frisch aus dem GURU-BOARD. Klingt nicht gut, ist was dran - aber ich bleib trotzdem drin...

( http://www.guruboard.com/commentary/default.asp?aid=252 )

Featured stock - DCGN
by Greg Fry on 2/1/2004 4:10:33 PM

DCGN (deCODE genetics, Inc., Biotechnology and Drugs) $10.80 - Sell. With the markets teetering, the Street uncomfortable with the Fed`s outlook, and most charts looking like ski ramps, we`re taking this week to point out several stocks we feel are ready for inevitable corrections. First up is biotech short candidate DCGN. DCGN is a population genetics company developing drugs and DNA-based diagnostics based on its discoveries in the inherited causes of common diseases. The Company`s business is divided into two components, products and services. Its service offerings include contract service businesses in drug discovery and medicinal chemistry, three-dimensional protein crystallography products and contract services, pharmacogenomics and clinical trials services, database services and genotyping services.Keep in mind, with these short recommendations, that we are basing our thoughts on overall market conditions and technical indicators - this is not any sort of indictment of the companies or their long-term prospects, but rather a realistic analysis relying on the laws of gravity that what goes up must come down. We are all for companies using advanced scientific means to combat disease, and would love to someday see DCGN trading at $100 per share... we just don`t think that time is now. DCGN has enjoyed a more-than-healthy run since Aug. 2003 when it traded at $2.45. Over the 52-week period, the stock is up 419% and in our view has entered into the land of the overbought and overvalued. In terms of growth, the company cannot be faulted - for the nine months ended Sept. 30, 2003, revenues increased 48% to $35.1 million while net loss before acct. change fell 80% to $24.6 million. Still, at current prices, the stock now is trading at 5.6x book value of $1.90 and 10.94x sales... by no means is it cheap here. Other numbers also point to a questionable valuation here, with a return on assets of -17% and a return on equity of -30% and operating and profit margins of -67% each. Over the last two weeks, the stock has started to exhibit signs of exhaustion, with a big pop followed by lower intraday lows. Thursday was a key example with the stock reaching an intraday low of $10.28 and crossing below its 13-day MA on unusually high volume of over 1 million shares traded. Friday`s close, on lower volume, took DCGN back above the 13-day, but on lower volume. The support of the 13-day is our critical gauge here - if DCGN closes below that level, we`ll view this as an entry signal, with a target closer to the 50-day MA of $8.80. The MACD here is resting right on the line and is pointing negative. We would use the recent high of $11.49 as a stop. Take a look at the insider transactions and you`ll see that officers have been selling over the last couple months at levels below today`s price, in the upper $7.00 range. Short-term price target: $8.90 (18% gain) Stop loss trigger: $11.50 (6% loss)

[tui66]

Seitenwärtsbewegung beendet?
11,31$ - schönes Volumen

interessanter Artikel http://www.forbes.com/nosection/forbes/2004/0216/141.html

[tui66]

wann fällt die 12,50$???
WARUM INTERESSIERT DAS HIER NIEMAND??

[tui66]

13$$$???? wir kommen. Chart ist nach oben frei!

[pegau]

Ich finde es auch kaum zu glauben, dass sich hier niemand für Decode interessiert. Die News kommen immer in D vorbörslich, d.h. lange bevor die Amis reagieren können, aber dennoch werden immer nur ein paar tausend Stück umgesetzt. Der Chart ist wirklich bis $25 frei...

http://finance.yahoo.com/q/bc?s=DCGN&t=1d

[MONSIEURCB]

Seid doch froh, dass hier nicht das übliche Schwätzer-Tohuwabohu herrscht - wer in diesen Wert investiert ist, weiß warum und stellt wohl auch etwas höhere "börsianische", ethische und intellektuelle Ansprüche...freuen wir uns auf das Knacken der 13, auch wenn`s abergläubisches Unheil bringt

[MONSIEURCB]

Jackpot!!!!
Kooperation mit Merck - das Warten hat sich gelohnt...jetzt geht`s erst richtig los! Heute 13 Dollar...Kurziel 29!
"Monse" Chris (champagnerentkorkenderweise ;-)

[Erbse1]

FOR IMMEDIATE RELEASE

Contacts:
deCODE genetics Euro RSCG Life NRP
Edward Farmer Joy Bessenger Ernie Knewitz
[phone] [phone] [phone]
[e-mail] [e-mail] [e-mail]
deCODE and Merck & Co., Inc. Form Broad Drug Development Alliance

deCODE will conduct information-rich clinical trials for Merck compounds, leveraging population and genetics data to optimize the clinical development and therapeutic potential of new drugs

Reykjavik, ICELAND, February 26, 2004 — deCODE genetics (NasdaqCGN) today announced the formation of a seven-year alliance with Merck & Co., Inc. (NYSE:MRK) under which deCODE will conduct information-rich clinical trials on a range of Merck’s developmental compounds. deCODE will at any given point over the course of the alliance be conducting concurrent trials on as many as five Merck compounds. The alliance will employ deCODE’s population genetics capabilities and expertise in pharmacogenomic analysis to enhance and complement Merck’s on-going clinical development process. deCODE’s population approach facilitates the selection of optimal trial cohorts and the analysis of patient responsiveness to drugs in relation to a range of phenotypic and genetic data. On the basis of trial results for particular compounds, the companies may also pursue the development of pharmacogenomic tests to identify patients for whom a given drug may be particularly effective.

Under the terms of the agreement, deCODE will receive royalties on sales of drugs and diagnostics developed as part of the alliance. deCODE will also receive a one-time technology access fee, will share research funding for the clinical development of compounds and pharmacogenomic analysis, and will receive milestone payments as compounds or pharmacogenomic tests reach the market. In addition, Merck has purchased $10 million of deCODE common stock at a price of $14.50 per share, and has received a warrant to purchase up to $50 million of additional shares of deCODE stock at $29.00 per share over the next five years.

“This is an exciting opportunity for us to apply our know-how in human genetics to information-rich clinical trials, and to add value to and participate in the next generation of Merck drugs,” said Dr. Kari Stefansson, CEO of deCODE. “Just as we have done in the design of our own drug development programs, we will be providing Merck the ability to go beyond testing developmental compounds against static endpoints alone. With our ability to integrate into clinical trials detailed data on many other variables – disease subtypes, biomarkers, genotypes and gene expression patterns – it is possible to leverage the clinical development studies to understand not just whether people respond to drugs, but also who responds best and why. We believe this is a crucial means for managing risk in the development process, and for maximizing the patient benefit and market potential of new drugs.”

“We are excited about this opportunity to partner with deCode to conduct enhanced clinical trials of compounds in important disease areas,” said Dr. Stephen Friend, senior vice president for Molecular Profiling and Basic Cancer Research at Merck Research Laboratories. “Our collaboration with deCode complements the molecular profiling technology gained through Merck’s acquisition of Rosetta and which we have integrated throughout our drug development efforts.”

About deCODE
deCODE is using population genetics to create a new paradigm for healthcare. With its uniquely comprehensive population data, deCODE is turning research on the genetic causes of common diseases into a growing range of products and services — in pharmaceuticals, gene and drug discovery, DNA-based diagnostics, pharmacogenomics, bioinformatics, and clinical trials. deCODE’s pharmaceuticals group, based in Chicago, and deCODE’s biostructures group, based in Seattle, conduct downstream development work on targets derived from deCODE’s proprietary research in human genetics as well as contract service work for pharmaceutical and biotechnology companies. deCODE is delivering on the promise of the new genetics.SM Visit us on the web at www.decode.com.

[MONSIEURCB]

EDGAR SEC-Filing!

View: Annual Data | Quarterly Data All numbers in thousands
PERIOD ENDING 30-Sep-03 30-Jun-03 31-Mar-03 31-Dec-02
Total Revenue 12,763 10,536 11,842 17,383
Cost of Revenue - (19,510) 19,510 -
Gross Profit 12,763 30,046 (7,668) 17,383
Operating Expenses
Research Development 10,891 36,303 322 19,757
Selling General and Administrative 4,166 3,228 4,581 7,671
Non Recurring 115 791 - -
Others - - - -
Total Operating Expenses - - - -
Operating Income or Loss (2,409) (10,276) (12,571) (10,045)
Income from Continuing Operations
Total Other Income/Expenses Net 1,949 905 445 53
Earnings Before Interest And Taxes (460) (9,371) (12,126) (9,992)
Interest Expense 826 861 916 880
Income Before Tax (1,286) (10,232) (13,042) (10,872)
Income Tax Expense - - - -
Minority Interest - - - -
Net Income From Continuing Ops (1,286) (10,232) (13,042) (10,872)
Non-recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Changes - - - -
Other Items - - - -
Net Income (1,286) (10,232) (13,042) (10,872)
Preferred Stock And Other Adjustments - - - -
Net Income Applicable To Common Shares ($1,286) ($10,232) ($13,042) ($10,872)

[blaueberge]

falls es noch jemand interessieren sollte.
wie wir alle sehen befindet decode sich in einem schönen abwärtstrend.
schön, weil ich schon lange draussen bin, aber langsam wird der wert wieder interessant, insbesondere weil ende august wichtige news anstehen. es geht um dieses herzmedikament und wenn die ergebnisse aus den tests positiv verlaufen sind, bekommt decode wohl nen ordentlichen batzen.
mir wurde zugetragen, dass es bis ende des jahres noch steil bergauf gehen sollte...

aber erstmal den abwärtstrend gebrochen sehen.

[MONSIEURCB]

Decode ist eindeutig ein Langfrist-Investment - drin bleiben und abwarten! Ich rechne mit deutlich zweistelligen Kursen bis Ende des Jahres...

[Guru-Schreck]

(©BörseGo - http://www.boerse-go.de)

DeCode Genetics hat heute gemeldet, dass Pricewaterhouse Coopers am 19. August von der Funktion als unabhängiger Wirtschaftsprüfer des Unternehmens zurückgetreten ist. Es gebe mit PWC aber keinerlei Meinungsverschiedenheiten über Bilanzierungspraktiken oder die Abschlüsse der vergangenen Jahre und die Rechnungslegung des laufenden Jahres.

Die Aktie des Biotech-Unternehmens, die heute im regulären Handel bereits 4,26 Prozent abgegeben hatte, bricht nachbörslich um derzeit 20,63 Prozent auf 5,00 Dollar ein.

[Erbse1]

deCODE genetics Announces Resignation of Independent Accountants

No disagreements with accountants on accounting principles or practices

Reykjavik, ICELAND, August 26, 2004 – deCODE genetics, Inc. (Nasdaq DCGN) today announced the filing of a Form 8-K with the Securities and Exchange Commission relating to the August 19, 2004 resignation of PricewaterhouseCoopers (PwC) as deCODE’s independent registered public accounting firm. PwC had acted as deCODE’s independent registered public accounting firm since deCODE’s formation in 1996.

During deCODE’s fiscal years ended December 31, 2003 and 2002 and the period from January 1, 2004 through August 19, 2004 there were no disagreements with PwC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure which disagreements, if not resolved to PwC’s satisfaction, would have caused PwC to make reference thereto in their reports on the financial statements for such years.

The Audit Committee of deCODE’s Board of Directors is actively engaged in retaining a new accounting firm.

[wohinistmeinGeld]

Das dürfte eigentlich nicht so tragisch sein. Mit Partnern wie Roche, Merck und Wyeth hat Decode starke Partner.
Also Nachkaufkurse.

[e.1]

ich versuche welche zu bekommen, aber klappt nicht
Allerdings hat mich dieser Abschlag schon etwas geschockt

[wohinistmeinGeld]

solange nicht eine echte Hiobsbotschaft kommt, was ich mir bei den Partnern echt nicht vorstellen kann, dann hoffe ich mal auf ähnliches wie bei Imclone, totale Überreaktion und dann ein Weihnachtsgeschenk.

[blaueberge]

decode wird im yahoo board ausführlich diskutiert:
http://messages.yahoo.com/bbs?action=t&type=r&board=yahoo.79…

[therman]

Hi,

die Phase II Tests für das Medikament gegen Herzinfarkt
werden demnächst beendet. Die Ergebnisse werden also bald
da sein.
Sind sie positiv, was wahrscheinlich ist, wird dies der
Aktie einen guten Schub geben.

therman

[wohinistmeinGeld]

die studien sind bereits beendet, die Ergebnisse können also jeden Tag kommen. Ich hab mal ein wenig Geld locker gemacht und für 4,7 nachgekauft, jatzt können sie melden.

[therman]

Hi,

gute Nachrichten.

DCGN hat die langfristige Abwärtstrendlinie seit Ende
Februar 2004 nach oben überwunden und ist damit aus
aus einem ausgedehnten Bullkeil nach oben ausgebrochen.

strong buy

Und:

Reykjavik, Iceland, September 10, 2004
deCODE genetics Announces Appointment of Deloitte & Touche as Independent Accountants

deCODE genetics, Inc. ,Nasdaq DCGN, today announced that it has appointed Deloitte & Touche LLP as its new independent registered public accounting firm, effective immediately.

"Deloitte has a dedicated and experienced team that shares our commitment to best-practice accounting and reporting standards," said Lance Thibault, Chief Financial Officer of deCODE. "We look forward to working with them."

therman

[blaueberge]

yebs, darauf hab ich gewartet. die schlechte nachricht von dem zurücktreten von PWC, dem vorherigen wirtschaftsprüfungsunternehmen ist damit überwunden und in den nächsten tagen/wochen wird es die news über die ergebnisse der phaseIIa tests von dem herzinfaktvorbeugemedikament (schöne übersetzung) geben.

ich werde versuchen am montag welche zu bekommen. vielleicht gibt`s ja noch einen kleinen rücksetzer...

[wohinistmeinGeld]

Wir werden dieses Jahr problemlos wieder das alte Jahreshoch sehen. Also mit dem Rücksetzer wird das wohl nichts mehr.

[Erbse1]

deCODE Awarded $24 million by NIH to Study Genetics of Infectious Disease and Vaccine Response

Reykjavik, ICELAND, October 8, 2004 ― deCODE genetics (NasdaqCGN) today announced that it has been awarded a five-year, $23.9 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health. Under the contract, deCODE will apply its population approach and resources to discover genetic factors associated with susceptibility to certain infectious diseases and with vaccine response. deCODE will be working with scientists at the University of New Mexico (UNM) to conduct functional validation of biological pathways discovered through its genetics research. The National Center for Genome Resources (NCGR) will provide bioinformatics resources to make study information and results available to the scientific community.

The contract recognizes deCODE’s global leadership in the discovery of the genetic basis of disease risk and drug response. deCODE will conduct genome-wide scans in Iceland to search for key genes involved in susceptibility to tuberculosis; adverse reaction to smallpox vaccination; and susceptibility to influenza and certain bacterial infections, such as those that cause pneumonia and meningitis. The identification of genes involved in susceptibility to infectious diseases promises to provide a foothold in the biology of these conditions and a starting point for developing better drugs to treat them and vaccines to prevent them. C. Rick Lyons, M.D., Ph.D. of the UNM Health Sciences Center in Albuquerque, New Mexico, a renowned expert in the study of common pathogens and microbial virulence, will lead the functional work on targets identified by deCODE. The NCGR, a research institute based in Santa Fe, New Mexico, and headed by Dr. Stephen Kingsmore, will design and maintain an Immune Response Database (IRDB), an internet-based resource that will enable investigators to query and visualize the results of this project in the context of existing data on the genetics of immune response.

“We are excited by this project and by the opportunity to bring together our expertise and capabilities with those of two leading New Mexico research organizations,” said Kari Stefansson, CEO of deCODE. “I believe this project reflects the commitment of the NIAID to seek out the best science and apply it to problems that are critical to human health. The international character of this collaboration is also appropriate to the goal – to utilize human genetics to improve our ability to prevent and treat serious challenges to public health around the globe.”

"This contract is an endorsement of the world-class disease research at UNM Health Sciences Center," said Bill Richardson, Governor of New Mexico. "My administration is working to leverage the outstanding R&D in New Mexico to develop new companies and new jobs. We look forward to working in partnership with deCODE, the National Center for Genome Resources and the National Institutes of Health to develop new drugs to battle infectious diseases and, at the same time, create good jobs here in New Mexico."

This project is funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract number HHSN266200400064C.

[wohinistmeinGeld]

na geht doch

[wohinistmeinGeld]

23.11. 09:00
Roche: Zusammenarbeit mit Decode Genetics im Bereich Gefässerkrankungen
Basel (AWP) - Die Roche Holding AG und die an der Nasdaq kotierte Decode Genetics Inc, mit Sitz in Reykjavik, gehen eine Zusammenarbeit über drei Jahre bei der Entwicklung und Vermarktung von Phosphodiesterase 4(PDE4), ein Hemmer zur Prophylaxe und Behandlung von Gefässkrankheiten (u.a. Schlaganfälle), ein. Dies geht aus einer Medienmitteilung von Dienstag hervor.

Decode wird dabei ihre Kapazitäten beim Design strukturbasierter Arzneimittel nutzen, um Leitsubstanzen zu optimieren und deren Entwicklung in die Wege zu leiten, heisst es. Die beiden Vertragspartner werden sich gemäss dem Abkommen die Kosten von Forschung und klinischen Tests teilen. Decode kann zudem Meilensteinzahlungen und umsatzbezogene Lizenzgebühren erhalten, heisst es.

jb/cs/mk

[Erbse1]

deCODE to Conduct Phase II Clinical Trial in Asthma

Reykjavik, ICELAND, December 17, 2004 – deCODE genetics (Nasdaq: DCGN) today announced the signing of an agreement under which it will conduct a Phase II information-rich clinical trial next year of a third-party compound as part of a drug development program in asthma. The compound targets the product of a gene deCODE has shown to play an important role in the development of asthma. The trial will leverage deCODE’s extensive population research in asthma and enrollment is expected to begin in early 2005. Neither the name of the company nor of the compound was disclosed.

“This is another example of how our gene discovery work has led us to targets against which promising compounds have been developed by others in other indications. This approach enables us to leapfrog over several years of drug discovery and development and to go straight into information-rich trials, accelerating the application in the clinic of our gene discoveries and generating product-driven value for the company,” said Kari Stefansson, CEO of deCODE.